Developer docs
API playgroundTry for free, no card

Search company profiles

Remmie

Full company profile

uuid0000iqz

Namestring
Remmie
Legal namestring
Remmie Inc.
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Remmie Inc. is a women-founded digital health company that develops and markets connected otoscopes and a paired AI-powered telehealth platform for ear, nose, and throat assessment, primarily targeting parents of children with recurrent ear infections and healthcare providers delivering telehealth ENT care. The company operates from Washington and California, designing hardware in California and operating sales, customer support, and provider partnerships out of Seattle with extension offices in San Francisco, Los Angeles, Spokane, and London. The product portfolio includes Remmie 4 (FDA-registered USB-connected AI otoscope at $149), Remmie 3 (Wi-Fi enabled otoscope at $149), and Remmie Pro (FDA-registered, CE-marked, Health Canada- and Australian TGA-cleared professional digital otoscope), with a clinician-reviewed subscription service (Remmie Care) and pre-visit assessment platform (Remmie Report). The proprietary Remmie.ai diagnostic engine, a multi-modal deep learning model analyzing eardrum images paired with symptom text, is under NIH SBIR Phase 2-funded development with Lurie Children's Hospital targeting FDA approval as a medical device.

Remmie generates revenue through a hybrid hardware-plus-subscription model: one-time device sales ($149 consumer devices; pro pricing not publicly disclosed) plus recurring Remmie Care subscriptions ($10/month or $25 per submission), Remmie Report basic plan ($12/year), and consumable specula accessories ($10 for 10 pieces, $50 for 50 pieces). Distribution is multi-channel: own DTC e-commerce at remmiehealth.com, Amazon marketplace, four global distributors covering the UK, Australia, and Canada, and direct B2B sales to healthcare providers. Enterprise footprints include 300+ accounts, 20+ clinics, 6 school districts, and 2 US hospital pilots, alongside B2B2C integrations with telehealth partners including Poppins (7 U.S. states), Rocket Doctor, CareClix, MyTelemedicine, PM Pediatrics, QDoc, Kavira, and Nextera. Non-dilutive NIH funding (~$3M SBIR Phase 2) and prior accelerator backing (Techstars, Plug and Play, Sunstone Management) support ongoing R&D.

The company has filed four patent applications protecting Remmie.ai methods and maintains HIPAA-compliant AWS cloud infrastructure with HL7/FHIR EMR integration. Customer-reported outcomes include 67% of users avoiding an in-person doctor's visit, 90% willingness to recommend, $2,032 average cost savings per avoided ER visit, 47 NPS, 80% engagement at 6 months, and a 3.9-star Amazon rating. Reported market context cites $4 billion in annual U.S. healthcare spending on ear infection diagnosis, 16 million annual episodes, and 5 of 6 children experiencing ear infections before age three.

Short descriptiontext

Remmie develops FDA-registered connected otoscopes (Remmie 4, 3, Pro) paired with HIPAA-compliant telehealth subscriptions (Remmie Care, Remmie Report) and a NIH-funded AI diagnostic engine (Remmie.ai), serving parents of children with ear infections and clinicians delivering ENT telehealth.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersCulver City, United States
HQ citystring
Culver City
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices5 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
digital otoscope devices, telehealth ENT solutions, AI ear diagnostics, home medical imaging, pediatric telehealth hardware
Industry3 codes
PRIMARYHLALAGAM
ENT (Otolaryngology) Telemedicine Platforms
Healthcare & Life Sciences/Telehealth Platforms/Specialty Telemedicine Platforms (e.g., dermatology, cardiology, neurology)
SECONDARYHLAHABAL
Portable, Mobile & Point-of-Care Imaging Systems
Healthcare & Life Sciences/Medical Devices & Diagnostics/Medical Imaging & Radiology Equipment
SECONDARYHLACAPAJ
Medical Device Connectivity & Interoperability Middleware (MDI, EHR/HL7/FHIR Integration)
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare IoT & Remote Patient Monitoring
NAICS code1 code
  • Surgical and Medical Instrument Manufacturing339112
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Digital Otoscope Devices
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model5 records
1Hardware Device Sales
TypeHardware Sales
Description

Sale of digital otoscope devices (Remmie 3, Remmie 4, Remmie Pro) directly to consumers and healthcare providers. One-time hardware purchase with optional subscription services.

remmiehealth.com
2Remmie Care Subscription
TypeSubscription Recurring
Description

Monthly subscription service ($10/month) providing pre-visit assessment with clinician review, 24-hour turnaround for findings, and ability to email submissions to physicians. Also per-submission option at $25.

remmiehealth.com
3Remmie Report
TypeSubscription Recurring
Description

Annual subscription plan ($12/year) with 1 review credit annually for basic assessment services.

remmiehealth.com
4NIH SBIR Grant Funding
TypeLicensing Royalties
Description

Nearly $3 million SBIR Phase 2 grant from NIH NIDCD for development of Remmie.ai diagnostic tool.

remmiehealth.com
5Enterprise/Provider Contracts
TypeManaged Services
Description

B2B contracts with healthcare organizations, clinics, hospital networks, and school districts for deployment of Remmie Care platform with volume pricing.

remmiehealth.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels6 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Supply Chain, Marketing or Sales, Operations, Infrastructure
Pricing details8 tiers
1Remmie 4 - USB-connected AI otoscope
ModelOne time/ perpetual licenseBilling cadenceMonthly
Notes

$149 per device. Includes otoscope, free app, and 30-day clinician's review trial.

remmiehealth.com
2Remmie 3 - Wireless Wi-Fi otoscope
ModelOne time/ perpetual licenseBilling cadenceMonthly
Notes

$149 per device. Next generation intelligent home otoscope with AI-guided features.

remmiehealth.com
3Remmie Pro - Professional medical device
ModelOne time/ perpetual licenseBilling cadenceMonthly
Notes

Price not publicly listed. FDA-registered, CE Mark, Health Canada MDEL, Australian TGA-cleared. For medical professionals.

remmiehealth.com
4Remmie Care - BYOD subscription
ModelSubscriptionBilling cadenceMonthly
Notes

$10/month subscription only (no device). Includes pre-visit assessment, 24hr clinician turnaround, email submissions to physician.

remmiehealth.com
5Remmie Care - Per submission
ModelUsage-basedBilling cadencePay-as-you-go
Notes

$25 per submission if no subscription. Device required separately ($149).

remmiehealth.com
6Remmie Report Basic Plan
ModelSubscriptionBilling cadenceAnnual
Notes

$12/year ($1/month) includes 1 review credit annually. Purchase in Remmie app.

remmiehealth.com
7Specula Set (50 pieces)
ModelUnit PricingBilling cadencePay-as-you-go
Notes

$50 for 50 disposable specula pieces (3.7mm diameter).

remmiehealth.com
8Specula Set (10 pieces)
ModelUnit PricingBilling cadencePay-as-you-go
Notes

$10 for 10 disposable specula pieces (3.7mm diameter).

remmiehealth.com
GTM typeB2B and B2C
B2B and B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1Remmie Report
Description

AI-powered ear-nose-throat pre-visit assessment platform enabling patients to capture images and receive clinician review asynchronously.

remmiehealth.com
+2 more records
Core offering1 text field

Remmie designs, manufactures and sells FDA-registered digital otoscope devices (Remmie 3, Remmie 4, Remmie Pro) that connect to smartphones, tablets and computers to capture ear, nose and throat imagery for at-home examination and telehealth consultations. The hardware is paired with subscription telehealth services (Remmie Care and Remmie Report) that route captured images to clinicians for remote review, and an in-development AI diagnostic engine (Remmie.ai) for automated ENT disease classification.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 67% of customers avoided an in-person doctor's visit
+5 more records
Product overview1 text field

Remmie Health offers a portfolio of FDA-registered digital otoscopes and AI-powered healthcare platforms for at-home ENT care. The product line includes Remmie 4 (USB-connected AI-powered otoscope with highest image quality), Remmie 3 (wireless Wi-Fi enabled intelligent home otoscope with AI guidance), and Remmie Pro (professional-grade digital otoscope for medical providers). These hardware products integrate with the Remmie Report platform and Remmie Care telehealth service for remote clinical assessment. The Remmie.ai AI diagnostic engine is under development for ENT disease classification. Accessories include disposable specula sets. All devices enable patients to capture ear, nose, and throat images and videos for telehealth consultations with clinicians.

Product and service6 records
1Remmie 4
CategoryDigital otoscope hardware
Description

FDA-registered USB-connected AI-powered otoscope for at-home ear, nose, and throat examinations on phones, tablets, and computers. Features HD720p resolution, 3.7mm diameter lens, USB Type-C connection, IP67 waterproof design, and works in 60 seconds without Wi-Fi. Includes 30-day Remmie Care clinician review trial and is FSA/HSA eligible.

2Remmie 3
CategoryDigital otoscope hardware
Description

Wireless Wi-Fi-enabled intelligent home otoscope with AI-guided image capture for ear, nose, and throat examination. Features HD720p resolution, 3.9mm diameter lens, 5 levels of adjustable brightness, and up to 30 fps video streaming. Compatible with iOS/iPadOS 14+ and Android 10+. FSA/HSA eligible at $149 per device.

3Remmie Pro
CategoryProfessional digital otoscope hardware
Description

FDA-registered digital otoscope designed for medical professionals, clinics and telemedicine providers. Features a 2 megapixel sensor (1920x1080), Wi-Fi connectivity, snapshot functionality, and store-and-forward capability for saving and sharing images and videos to EMR systems.

4Remmie Care
CategoryTelehealth subscription service
Description

Telehealth service connecting users with board-certified clinicians for ENT consultation. Offers a BYOD (bring your own device) subscription at $10/month, per-submission fee at $25, and integrates with platforms including CareClix ($50 cash visit), MyTelemedicine ($29.95/month subscription) and PM Pediatrics (telehealth in 15 states). Delivers 24-hour clinician turnaround for feedback on submissions.

5Remmie Report
CategoryAI-powered pre-visit assessment platform
Description

AI-powered ENT pre-visit assessment platform with a patient app and clinical portal. Patients capture ear, nose, and throat images and share health information; clinicians review remotely to guide patients to the right care. Basic consumer plan at $12/year includes one annual review credit; provider subscription includes 3 months of Remmie Care service and generates summary reports that can be sent via PDF email for upload to patient portals such as MyChart.

6Specula Set
CategoryOtoscope accessory / consumable
Description

Disposable specula (ear tips) for Remmie otoscopes. Soft-touch thermoplastic elastomer rubber (85° shore hardness) protects the ear canal. Available in packs of 10 ($10) or 50 ($50). 3.7mm diameter compatible with all Remmie otoscope models.

Scale indicator16 records

Each record includes

Type, Value, Description, Source

Partnership10 partners
Strategic tierCoreTypeGTM or Marketing PartnerAnnounced on2026-03-04
Description

Poppins partnered with Remmie Health to offer at-home telehealth solution for pediatric ear infections. Parents use Remmie's digital otoscope to capture video of child's eardrum and share with Poppins clinicians for remote diagnosis and prescription. Service marketed as concierge pediatric offering eliminating office visits. Available in 7 U.S. states: CT, FL, IL, NJ, NY, PA, TX. Plans starting at $29/month or $249/year.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-06-14
Description

Clinical research partnership for Remmie.ai development involving Chicago's Lurie Children's Hospital. Project aims to improve ENT diagnosis accuracy and reduce healthcare costs, progressing towards FDA approval as a medical device.

Strategic tierMinorTypeGTM or Marketing Partner
Description

Telehealth platform partner offering ENT consultations with Remmie integration. Listed as partner on website.

Strategic tierMinorTypeGTM or Marketing Partner
Description

Healthcare partner listed on company website partnerships section.

Strategic tierMinorTypeGTM or Marketing Partner
Description

Healthcare partner listed on company website partnerships section.

Strategic tierMinorTypeGTM or Marketing Partner
Description

Healthcare partner listed on company website partnerships section.

7CareClix
Strategic tierMinorTypeGTM or Marketing Partner
Description

Telehealth platform connecting Remmie users with board-certified clinicians for video consultations. Cash payment $50 per visit or subscription available.

remmiehealth.com
Strategic tierMinorTypeGTM or Marketing Partner
Description

Telehealth platform partner with $29.95/month subscription service for Remmie users seeking medical consultations.

Strategic tierMinorTypeGTM or Marketing Partner
Description

Pediatric urgent care provider offering telehealth services to Remmie users in 15 states, 8am-12am daily.

Strategic tierMinorTypeGTM or Marketing Partner
Description

Direct primary care ecosystem partner with Dr. Brad Brown testimonial praising Remmie for reducing unnecessary office visits.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Eko Health builds AI-powered digital stethoscopes with FDA-cleared cardiac AI and telehealth integration. Comparable hardware + AI diagnostic + telehealth platform model applied to a different body system (heart vs. ear), making it a relevant category analog for Remmie.ai's diagnostic ambitions.

TypeDirect peer
Description

Firefly Global manufactures digital video otoscopes and dermatoscopes used by medical professionals and for telehealth deployments. Closest direct competitor to Remmie Pro with similar professional-grade imaging specs, EMR integration, and telehealth-oriented positioning.

TypeDirect peer
Description

Bebird is the dominant consumer-priced smart otoscope brand, selling Wi-Fi connected ear scopes on Amazon at $30-60 with companion smartphone apps. Directly comparable product form factor and target consumer use case, though with no AI diagnostic or telehealth integration and at a fraction of Remmie's price point.

TypeOthers
Description

Caregility provides enterprise telehealth infrastructure for hospital systems, including virtual care platforms and clinical workflow tools. Adjacent to Remmie's enterprise go-to-market motion targeting health systems and could be a partnership or integration point rather than a direct competitor.

TypeDirect peer
Description

ScopeAround sells Wi-Fi and USB digital otoscopes for both consumer and medical professional use, with smartphone apps for image/video capture. Directly competes in the same hardware category, with overlapping SKU structure (consumer vs. pro) and similar Amazon DTC distribution.

TypeBroad incumbent
Description

Withings is an established consumer connected-health device company (smart scales, blood pressure monitors, sleep) sold through retail and DTC channels. Comparable hardware-led D2C model targeting health-conscious households, though without Remmie's specialty ENT/telehealth focus.

TypeBroad incumbent
Description

Welch Allyn is the incumbent leader in professional otoscopes and is now part of Baxter (via Hillrom). Provides the established clinical-grade otoscope baseline that telehealth solutions like Remmie Pro must integrate with or differentiate against in hospital and clinic settings.

TypeDirect peer
Description

TytoCare is the most direct peer — a telehealth platform built around a connected home examination device (Tyto) that enables remote auscultation, otoscopy, and throat imaging for clinicians. Both companies combine FDA-cleared hardware with a clinician review subscription and sell into telehealth partners, health systems, and school programs.

TypeEmerging player
Description

Anytime Pediatrics is a pediatric telehealth platform offering on-demand virtual care to children, founded by Remmie Clinical Advisor Mick Connors. Comparable in serving pediatric telehealth demand that drives demand for Remmie devices, and represents the software platform side of the combined offering.

TypeDirect peer
Description

CellScope pioneered the smartphone otoscope (Oto Home) for at-home ear exams and telehealth, and was acquired by ResMed. Conceptually identical model to Remmie — consumer otoscope device paired with asynchronous clinician review — and represents the strategic exit benchmark for the category.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers11 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
Yes

Docs URL, Description

Integration5 records

Each record includes

Title, Type, Description, Source

AI capability8 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance7 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Remmie

Digital Otoscope Devicesremmiehealth.com

Remmie develops FDA-registered connected otoscopes (Remmie 4, 3, Pro) paired with HIPAA-compliant telehealth subscriptions (Remmie Care, Remmie Report) and a NIH-funded AI diagnostic engine (Remmie.ai), serving parents of children with ear infections and clinicians delivering ENT telehealth.

What Remmie does

Remmie Inc. is a women-founded digital health company that develops and markets connected otoscopes and a paired AI-powered telehealth platform for ear, nose, and throat assessment, primarily targeting parents of children with recurrent ear infections and healthcare providers delivering telehealth ENT care. The company operates from Washington and California, designing hardware in California and operating sales, customer support, and provider partnerships out of Seattle with extension offices in San Francisco, Los Angeles, Spokane, and London. The product portfolio includes Remmie 4 (FDA-registered USB-connected AI otoscope at $149), Remmie 3 (Wi-Fi enabled otoscope at $149), and Remmie Pro (FDA-registered, CE-marked, Health Canada- and Australian TGA-cleared professional digital otoscope), with a clinician-reviewed subscription service (Remmie Care) and pre-visit assessment platform (Remmie Report). The proprietary Remmie.ai diagnostic engine, a multi-modal deep learning model analyzing eardrum images paired with symptom text, is under NIH SBIR Phase 2-funded development with Lurie Children's Hospital targeting FDA approval as a medical device.

Remmie generates revenue through a hybrid hardware-plus-subscription model: one-time device sales ($149 consumer devices; pro pricing not publicly disclosed) plus recurring Remmie Care subscriptions ($10/month or $25 per submission), Remmie Report basic plan ($12/year), and consumable specula accessories ($10 for 10 pieces, $50 for 50 pieces). Distribution is multi-channel: own DTC e-commerce at remmiehealth.com, Amazon marketplace, four global distributors covering the UK, Australia, and Canada, and direct B2B sales to healthcare providers. Enterprise footprints include 300+ accounts, 20+ clinics, 6 school districts, and 2 US hospital pilots, alongside B2B2C integrations with telehealth partners including Poppins (7 U.S. states), Rocket Doctor, CareClix, MyTelemedicine, PM Pediatrics, QDoc, Kavira, and Nextera. Non-dilutive NIH funding (~$3M SBIR Phase 2) and prior accelerator backing (Techstars, Plug and Play, Sunstone Management) support ongoing R&D.

The company has filed four patent applications protecting Remmie.ai methods and maintains HIPAA-compliant AWS cloud infrastructure with HL7/FHIR EMR integration. Customer-reported outcomes include 67% of users avoiding an in-person doctor's visit, 90% willingness to recommend, $2,032 average cost savings per avoided ER visit, 47 NPS, 80% engagement at 6 months, and a 3.9-star Amazon rating. Reported market context cites $4 billion in annual U.S. healthcare spending on ear infection diagnosis, 16 million annual episodes, and 5 of 6 children experiencing ear infections before age three.

Remmie firmographics

Firmographics
Name
Remmie
Legal name
Remmie Inc.
Website
https://remmiehealth.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
11–50 employees
Short description
Remmie develops FDA-registered connected otoscopes (Remmie 4, 3, Pro) paired with HIPAA-compliant telehealth subscriptions (Remmie Care, Remmie Report) and a NIH-funded AI diagnostic engine (Remmie.ai), serving parents of children with ear infections and clinicians delivering ENT telehealth.
Ownership category
akta.pro rank

Remmie industry classification

Industry
Product category
Digital Otoscope Devices
NAICS
Surgical and Medical Instrument Manufacturing (339112)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLALAGAM
ENT (Otolaryngology) Telemedicine Platforms
Healthcare & Life Sciences/Telehealth Platforms/Specialty Telemedicine Platforms (e.g., dermatology, cardiology, neurology)
SECONDARYHLAHABAL
Portable, Mobile & Point-of-Care Imaging Systems
Healthcare & Life Sciences/Medical Devices & Diagnostics/Medical Imaging & Radiology Equipment
SECONDARYHLACAPAJ
Medical Device Connectivity & Interoperability Middleware (MDI, EHR/HL7/FHIR Integration)
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare IoT & Remote Patient Monitoring

Keywords

  • Digital otoscope devices
  • Telehealth ENT solutions
  • AI ear diagnostics
  • Home medical imaging
  • Pediatric telehealth hardware

Where Remmie is headquartered

Location

Headquarters

HQ city
Culver City
HQ country
United States
HQ region
North America

Offices5 records

Markets served

Remmie business model

Business model
GTM type
B2B and B2C
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Supply Chain, Marketing or Sales, Operations, Infrastructure

Revenue model

  1. Hardware Device Sales: Sale of digital otoscope devices (Remmie 3, Remmie 4, Remmie Pro) directly to consumers and healthcare providers. One-time hardware purchase with optional subscription services.
  2. Remmie Care Subscription: Monthly subscription service ($10/month) providing pre-visit assessment with clinician review, 24-hour turnaround for findings, and ability to email submissions to physicians. Also per-submission option at $25.
  3. Remmie Report: Annual subscription plan ($12/year) with 1 review credit annually for basic assessment services.
  4. NIH SBIR Grant Funding: Nearly $3 million SBIR Phase 2 grant from NIH NIDCD for development of Remmie.ai diagnostic tool.
  5. Enterprise/Provider Contracts: B2B contracts with healthcare organizations, clinics, hospital networks, and school districts for deployment of Remmie Care platform with volume pricing.

Pricing tiers

ModelBillingPrice
One time/ perpetual licenseMonthlyRemmie 4 - USB-connected AI otoscope
One time/ perpetual licenseMonthlyRemmie 3 - Wireless Wi-Fi otoscope
One time/ perpetual licenseMonthlyRemmie Pro - Professional medical device
SubscriptionMonthlyRemmie Care - BYOD subscription
Usage-basedPay-as-you-goRemmie Care - Per submission
SubscriptionAnnualRemmie Report Basic Plan
Unit PricingPay-as-you-goSpecula Set (50 pieces)
Unit PricingPay-as-you-goSpecula Set (10 pieces)

Go-to-market motion3 records

Distribution channels6 records

Marketing channels8 records

Remmie product offering

Product offering

Core offering

Remmie designs, manufactures and sells FDA-registered digital otoscope devices (Remmie 3, Remmie 4, Remmie Pro) that connect to smartphones, tablets and computers to capture ear, nose and throat imagery for at-home examination and telehealth consultations. The hardware is paired with subscription telehealth services (Remmie Care and Remmie Report) that route captured images to clinicians for remote review, and an in-development AI diagnostic engine (Remmie.ai) for automated ENT disease classification.

Product overview

Remmie Health offers a portfolio of FDA-registered digital otoscopes and AI-powered healthcare platforms for at-home ENT care. The product line includes Remmie 4 (USB-connected AI-powered otoscope with highest image quality), Remmie 3 (wireless Wi-Fi enabled intelligent home otoscope with AI guidance), and Remmie Pro (professional-grade digital otoscope for medical providers). These hardware products integrate with the Remmie Report platform and Remmie Care telehealth service for remote clinical assessment. The Remmie.ai AI diagnostic engine is under development for ENT disease classification. Accessories include disposable specula sets. All devices enable patients to capture ear, nose, and throat images and videos for telehealth consultations with clinicians.

Differentiator

Problem solved

Functional benefit

Brands

  • Remmie Report: AI-powered ear-nose-throat pre-visit assessment platform enabling patients to capture images and receive clinician review asynchronously.
  • Remmie Care
  • Remmie.ai

Products and services

  • Remmie 4 FDA-registered USB-connected AI-powered otoscope for at-home ear, nose, and throat examinations on phones, tablets, and computers. Features HD720p resolution, 3.7mm diameter lens, USB Type-C connection, IP67 waterproof design, and works in 60 seconds without Wi-Fi. Includes 30-day Remmie Care clinician review trial and is FSA/HSA eligible.
  • Remmie 3 Wireless Wi-Fi-enabled intelligent home otoscope with AI-guided image capture for ear, nose, and throat examination. Features HD720p resolution, 3.9mm diameter lens, 5 levels of adjustable brightness, and up to 30 fps video streaming. Compatible with iOS/iPadOS 14+ and Android 10+. FSA/HSA eligible at $149 per device.
  • Remmie Pro FDA-registered digital otoscope designed for medical professionals, clinics and telemedicine providers. Features a 2 megapixel sensor (1920x1080), Wi-Fi connectivity, snapshot functionality, and store-and-forward capability for saving and sharing images and videos to EMR systems.
  • Remmie Care Telehealth service connecting users with board-certified clinicians for ENT consultation. Offers a BYOD (bring your own device) subscription at $10/month, per-submission fee at $25, and integrates with platforms including CareClix ($50 cash visit), MyTelemedicine ($29.95/month subscription) and PM Pediatrics (telehealth in 15 states). Delivers 24-hour clinician turnaround for feedback on submissions.
  • Remmie Report AI-powered ENT pre-visit assessment platform with a patient app and clinical portal. Patients capture ear, nose, and throat images and share health information; clinicians review remotely to guide patients to the right care. Basic consumer plan at $12/year includes one annual review credit; provider subscription includes 3 months of Remmie Care service and generates summary reports that can be sent via PDF email for upload to patient portals such as MyChart.
  • Specula Set Disposable specula (ear tips) for Remmie otoscopes. Soft-touch thermoplastic elastomer rubber (85° shore hardness) protects the ear canal. Available in packs of 10 ($10) or 50 ($50). 3.7mm diameter compatible with all Remmie otoscope models.

Quantifiable outcome

  • 67% of customers avoided an in-person doctor's visit
  • +5 more outcomes

Companies that use Remmie

Customer profile

Named customers11 records

Segments5 records

Ideal customer profiles4 records

Remmie technology and API

Technology

Technology focussed Yes

API detail

Has API
Yes
API docs
API detail

Core technology

AI maturity

App detail

Integration5 records

AI capability8 records

Feature5 records

Remmie partnerships and signals

Strategic signal

Partnerships

Ten partnerships are on record, tiered core and minor.

  • PoppinscoreGTM or Marketing Partner · 4 March 2026Poppins partnered with Remmie Health to offer at-home telehealth solution for pediatric ear infections. Parents use Remmie's digital otoscope to capture video of child's eardrum and share with Poppins clinicians for remote diagnosis and prescription. Service marketed as concierge pediatric offering eliminating office visits. Available in 7 U.S. states: CT, FL, IL, NJ, NY, PA, TX. Plans starting at $29/month or $249/year.
  • Lurie Children's HospitalcoreStrategic or Co-development Partner · 14 June 2024Clinical research partnership for Remmie.ai development involving Chicago's Lurie Children's Hospital. Project aims to improve ENT diagnosis accuracy and reduce healthcare costs, progressing towards FDA approval as a medical device.
  • Rocket DoctorminorGTM or Marketing PartnerTelehealth platform partner offering ENT consultations with Remmie integration. Listed as partner on website.
  • KaviraminorGTM or Marketing PartnerHealthcare partner listed on company website partnerships section.
  • NexteraminorGTM or Marketing PartnerHealthcare partner listed on company website partnerships section.
  • QDocminorGTM or Marketing PartnerHealthcare partner listed on company website partnerships section.
  • CareClixminorGTM or Marketing PartnerTelehealth platform connecting Remmie users with board-certified clinicians for video consultations. Cash payment $50 per visit or subscription available.
  • MyTelemedicineminorGTM or Marketing PartnerTelehealth platform partner with $29.95/month subscription service for Remmie users seeking medical consultations.
  • PM PediatricsminorGTM or Marketing PartnerPediatric urgent care provider offering telehealth services to Remmie users in 15 states, 8am-12am daily.
  • Hint EcosystemminorGTM or Marketing PartnerDirect primary care ecosystem partner with Dr. Brad Brown testimonial praising Remmie for reducing unnecessary office visits.

Scale indicators16 records

Recent moves6 records

Expansion highlights6 records

Remmie competitors and assessment

Company assessment

Emerging players

  • Eko Health: Eko Health builds AI-powered digital stethoscopes with FDA-cleared cardiac AI and telehealth integration. Comparable hardware + AI diagnostic + telehealth platform model applied to a different body system (heart vs. ear), making it a relevant category analog for Remmie.ai's diagnostic ambitions.
  • Anytime Pediatrics: Anytime Pediatrics is a pediatric telehealth platform offering on-demand virtual care to children, founded by Remmie Clinical Advisor Mick Connors. Comparable in serving pediatric telehealth demand that drives demand for Remmie devices, and represents the software platform side of the combined offering.

Direct peers

  • Firefly Global: Firefly Global manufactures digital video otoscopes and dermatoscopes used by medical professionals and for telehealth deployments. Closest direct competitor to Remmie Pro with similar professional-grade imaging specs, EMR integration, and telehealth-oriented positioning.
  • Bebird: Bebird is the dominant consumer-priced smart otoscope brand, selling Wi-Fi connected ear scopes on Amazon at $30-60 with companion smartphone apps. Directly comparable product form factor and target consumer use case, though with no AI diagnostic or telehealth integration and at a fraction of Remmie's price point.
  • ScopeAround: ScopeAround sells Wi-Fi and USB digital otoscopes for both consumer and medical professional use, with smartphone apps for image/video capture. Directly competes in the same hardware category, with overlapping SKU structure (consumer vs. pro) and similar Amazon DTC distribution.
  • TytoCare: TytoCare is the most direct peer — a telehealth platform built around a connected home examination device (Tyto) that enables remote auscultation, otoscopy, and throat imaging for clinicians. Both companies combine FDA-cleared hardware with a clinician review subscription and sell into telehealth partners, health systems, and school programs.
  • CellScope (ResMed): CellScope pioneered the smartphone otoscope (Oto Home) for at-home ear exams and telehealth, and was acquired by ResMed. Conceptually identical model to Remmie — consumer otoscope device paired with asynchronous clinician review — and represents the strategic exit benchmark for the category.

Others

  • Caregility: Caregility provides enterprise telehealth infrastructure for hospital systems, including virtual care platforms and clinical workflow tools. Adjacent to Remmie's enterprise go-to-market motion targeting health systems and could be a partnership or integration point rather than a direct competitor.

Broad incumbents

  • Withings: Withings is an established consumer connected-health device company (smart scales, blood pressure monitors, sleep) sold through retail and DTC channels. Comparable hardware-led D2C model targeting health-conscious households, though without Remmie's specialty ENT/telehealth focus.
  • Welch Allyn (Hillrom / Baxter): Welch Allyn is the incumbent leader in professional otoscopes and is now part of Baxter (via Hillrom). Provides the established clinical-grade otoscope baseline that telehealth solutions like Remmie Pro must integrate with or differentiate against in hospital and clinic settings.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights6 records

Customer concentration

Remmie social profiles

Digital presence

Remmie compliance and trust

Trust signal

Compliance7 records

Remmie financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Remmie leadership team

Management profile

Number of profiles

Profiles9 records

Remmie funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Remmie M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Remmie

What does Remmie do?

Remmie designs, manufactures and sells FDA-registered digital otoscope devices (Remmie 3, Remmie 4, Remmie Pro) that connect to smartphones, tablets and computers to capture ear, nose and throat imagery for at-home examination and telehealth consultations. The hardware is paired with subscription telehealth services (Remmie Care and Remmie Report) that route captured images to clinicians for remote review, and an in-development AI diagnostic engine (Remmie.ai) for automated ENT disease classification.

Is Remmie a public or private company?

Remmie is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Remmie founded?

Remmie was founded in 2017. It employs 11 to 50 people.

Where is Remmie based?

Remmie is headquartered in Culver City, United States, in the North America region.

How does Remmie make money?

Five revenue lines are on record. Hardware Device Sales are the primary driver. The others are remmie Care Subscription, remmie Report, NIH SBIR Grant Funding and enterprise/Provider Contracts.

Who are Remmie's main competitors?

Emerging players on record are Eko Health and Anytime Pediatrics. Direct peers are Firefly Global, Bebird, ScopeAround, TytoCare and CellScope (ResMed). Caregility is listed as an others. Broad incumbents are Withings and Welch Allyn (Hillrom / Baxter).

Does Remmie have an API?

Yes. Remmie offers an API for remote symptoms examination that integrates with EMR and telemedicine systems. The API enables the Remmie.ai platform to process images of eardrums paired with symptom text descriptions for diagnostic assistance. Clinicians can access diagnosis support readouts, receive notifications for patient engagement, and generate reports for EMR integration. The API is commercially adopted for remote symptoms examination as integrated to EMR and telemedicine systems.

What industry is Remmie in?

Remmie's product category is Digital Otoscope Devices. Its primary akta.pro industry code is HLALAGAM, ENT (Otolaryngology) Telemedicine Platforms, with a secondary code of HLAHABAL, Portable, Mobile & Point-of-Care Imaging Systems. Its NAICS code is 339112 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Hey PoppinsFinally: Treat Ear Pain at Home With Poppins and RemmiePoppins and Remmie have partnered to offer an at-home telehealth solution for pediatric ear infections, allowing parents to use Remmie's digital otoscope to capture video of a child's eardrum and share it with Poppins clinicians for remote diagnosis and prescription. The service is marketed as a concierge pediatric offering that eliminates the need for office visits, with plans starting at $29/month or $249/year. The companies are currently available in seven U.S. states: Connecticut, Florida, Illinois, New Jersey, New York, Pennsylvania, and Texas.EIN PresswirePoppins Partners with Remmie Health to Enable At-Home Virtual Ear Infection DiagnosisPoppins announced a partnership with Remmie Health to enable at-home virtual ear infection diagnosis for children using the FDA-registered Remmie 4 AI-powered otoscope. The device allows parents to capture ear images on their smartphones in approximately 60 seconds, which Poppins pediatric clinicians then review to assess potential infections. Families in New York, New Jersey, Pennsylvania, Florida, Texas, and Illinois can now receive virtual evaluation for suspected ear infections without requiring an appointment.RemmiehealthRemmie Awarded NIH SBIR Phase 2 Grant for AI ENT PlatformRemmie Health has been awarded a nearly $3 million SBIR Phase 2 grant from the National Institute on Deafness and Other Communication Disorders (NIDCD) to develop its AI-based diagnostic platform, Remmie.ai. The two-year project will involve clinical research with Ann & Robert H. Lurie Children's Hospital of Chicago to advance the technology toward FDA designation as a Software as Medical Device.YahooRemmie Health Awarded NIH SBIR Phase 2 Grant for AI Ear-Nose-Throat (ENT) Diagnostic Assistance PlatformRemmie Health received a nearly $3 million NIH SBIR Phase 2 grant to develop Remmie.ai, an AI diagnostic assistance engine for ENT diseases. The grant supports clinical research with Lurie Children's Hospital and aims to advance the platform toward FDA SaMD designation.PR NewswireRemmie Health Awarded NIH SBIR Phase 2 Grant for AI Ear-Nose-Throat (ENT) Diagnostic Assistance PlatformRemmie Health received a nearly $3 million NIH SBIR Phase 2 grant to develop Remmie.ai, an AI diagnostic assistance engine for ENT diseases. The grant supports clinical research with Lurie Children's Hospital and aims to advance the platform toward FDA SaMD designation.Boston UniversityMy Big Idea: Helping Parents Avoid Repeated Trips to the Pediatrician’s OfficeBU alum Jane Zhang founded Seattle-based Remmie Health in 2018 to address the challenge of frequent pediatric visits for common ear, nose, and throat infections, developing the FDA-registered Remmie Dolphin wireless ear camera that transmits images to telehealth providers for remote diagnosis. The device, which uses AI-assisted analysis to help non-specialists diagnose conditions with specialist-level accuracy, is currently sold at CVS locations in Massachusetts and Rhode Island, on Amazon, and has accumulated 1,200 preorders from telehealth companies. Zhang, who holds a BU PhD in biomedical engineering and a UCLA MBA, aims to expand the product line to include additional at-home diagnostic tools like stethoscopes, thermometers, and blood pressure monitors.